Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best young stocks with huge upside potential.
Alto Neuroscience Inc. (ANRO)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Falcon Edge Capital Richard Gerson And Navroz D. Udwadia | 3,707,757 | $83,350,377 | 10.54% | |
| 2. | Commodore Capital Egen Atkinson And Michael Kramarz | 2,723,196 | $61,217,446 | +50% | 3.54% |
| 3. | Vestal Point Capital Ryan Wilder | 2,064,075 | $46,400,406 | -17% | 1.3% |
| 4. | Perceptive Advisors Joseph Edelman | 2,009,893 | $45,182,395 | +13% | 0.88% |
| 5. | Spruce Street Capital Alex Rosen And Simon Basseyn | 1,325,210 | $29,116,321 | +495% | 7% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.22 | 2,931 | $38,747.82 | 39,851 | 2024-07-10 | Filing | |
| $13.15 | 1,388 | $18,252.20 | 36,920 | 2024-07-09 | Filing | |
| $12.53 | 10,681 | $133,832.93 | 35,532 | 2024-07-09 | Filing | |
| $16.56 | 4,550 | $75,348.00 | 26,866 | 2024-03-28 | Filing | |
| $15.80 | 1,600 | $25,280.00 | 22,316 | 2024-03-28 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,207,025 | $27,133,922 | 0% | |
| 2. | 1,101,874 | $24,770,128 | 0.01% | |
| 3. | 666,188 | $14,975,907 | 0% | |
| 4. | 500,000 | $11,240,000 | 0.42% | |
| 5. | 500,000 | $11,240,000 | 0.58% |
News See All
12 Best Young Stocks with Huge Upside Potential
On September 15, Tom Sosnoff, Tastylive founder, joined 'Squawk Box' on CNBC to discuss the state of the IPO landscape and what to make of the surge of IPO offerings.
Alto Neuroscience's Depression Drug Shows Positive Biomarker Results in Phase 2 Trial
Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts.
13 Best IPO Stocks to Buy According to Wall Street Analysts
On August 14, Tony Kim, Centerview Partners co-president, joined CNBC's 'Closing Bell: Overtime' to discuss the IPO market and the dealmaking environment.
11 Best New Penny Stocks to Buy Right Now
On July 28, the Opening Bid team at Yahoo Finance and Victoria Fernandez, chief market strategist at Crossmark Global Investments, discussed the rise in cheap stock trading and what it can mean for the...
H.C. Wainwright Affirms Buy Rating on Alto Neuroscience (ANRO), Sets $10 PT
On Tuesday, H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Alto Neuroscience Inc. (NYSE:ANRO) and set a price target of $10.00.
Insiders are Piling into These 10 Healthcare Stocks in 2024
In this article, we will take a detailed look at Insiders are Piling into These 10 Healthcare Stocks in 2024. For a quick overview of such stocks, read our article Insiders are Piling into These 5 ...
Hedge Fund Resource Center